Inex/Enzon Marqibo to ODAC
Executive Summary
FDA's Oncologic Drug Products Advisory Committee will review Inex/Enzon's liposomal vincristine formulation Marqibo (formerly Onco TCS) Dec. 1, firms announce. Sponsors seek third-line monotherapy indication for treatment of relapsed aggressive non-Hodgkin's lymphoma. FDA lists Dec. 1 and 2 as tentative ODAC meeting dates. [Editor's Note: For more information, visit 1FDAAdvisoryCommittee.com]...
You may also be interested in...
Berlex Bonefos review
FDA's Oncologic Drugs Advisory Committee will discuss Berlex' NDA (21-776) for Bonefos (clodronate) as an adjuvant treatment for the reduction of occurrence of bone metastases in Stage II/III breast cancer patients on Dec. 2. Bonefos has an estimated user fee deadline of March 9, 2005. The committee will also review Ilex/Enzon's liposomal vincristine formulation Marqibo NDA (21-600) for relapsed aggressive non-Hodgkin's lymphoma and Ilex' Clolar (clofarabine) NDA (21-673) for pediatric patients (1-21 years) with refractory or relapsed acute leukemias on Dec. 1 (1"The Pink Sheet" Oct. 4, 2004, In Brief). The meeting will be held at the Holiday Inn in Silver Spring, Md. beginning at 8 a.m. on Dec. 1 and 8:30 a.m. on Dec. 2. [Editor's Note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.